04:00 p.m
Thursday 01 September 2022
d b a-
If you follow what is happening in the scientific arena recently with regard to Alzheimer’s disease, you may be wondering regarding the nature of this mistake that occurred and sparked controversy in the scientific community regarding ways to treat this disease that affects the mental functions of patients.
The beginning was when a new drug for the treatment of Alzheimer’s was announced in the name of “Adohelm” and obtained approval from the US Food and Drug Administration, and then it was later found that the benefits of this drug for Alzheimer’s patients are limited to the extent that insurance companies refused to cover the cost of this drug for most patients, he said. The website “Scitech Daily” specialized in scientific research.
After that, many drug companies announced stopping plans to develop a number of Alzheimer’s drugs, which they described as promising, following these drugs failed to achieve positive results in clinical trials.
Finally, a major scientific scandal erupted when evidence emerged revealing that some researchers had used fake x-rays in research on Alzheimer’s disease that had been published 16 years ago. This research was so important and reliable that many scholars and researchers later relied on it as the basis for their research work.
The question comes to mind regarding the connection of all these developments with each other and how they relate to the development process of drugs for the treatment of Alzheimer’s.
And it’s all regarding a protein substance in the human body called “Amyloid Progenitor Protein”, which is the substance that is deposited on the outer cortex of brain cells and causes the mental functions of patients to deteriorate. For years, this protein molecule has been the focus of Alzheimer’s treatment research and a key element in the research for a way to restore patients’ mental functions once more.
Researchers from the Alzheimer’s Treatment Center in the US state of Michigan and other research institutes have spent many years studying this amyloid protein in order to find answers to know the roots of Alzheimer’s and ways to prevent and treat it.
“It’s true that amyloid plays a role in brain disease and dementia, but Alzheimer’s is complex and involves more than just a single molecule,” says researcher Henry Paulson, director of the Alzheimer’s Center, who has dedicated a private lab at Michigan Medical School to treating dementia and other dementias for years. .
The scientific scandal relates to a type of amyloid protein called AB56, which has been described as a toxic protein that encourages plaque formation on brain cells. Paulson explains that he did not pay attention to this substance for many years, and attributed the reason for this to the fact that scientists did not achieve great success in reaching the same results that previous researchers claimed that they had reached.
Scitech Daily quoted Paulson as saying: “I am more concerned regarding the impact of this news on the public opinion of scientists, the delay in discovering this fraud is not ideal, and reveals the importance of scientists speaking transparently and publishing the results of their research even if their experiments fail to Proving the validity of the research of other scholars.
In general, scientists emphasize that there is ample evidence that middle-aged or elderly adults who want to reduce the risk of developing dementia or slow the progression of their disease must focus on healthy habits such as sleep, exercise, eating healthy food, and controlling blood pressure levels. and cholesterol in the body.
Paulson, a neurologist, says, “If you are in your 70s, I can’t tell you to go back in time, eat healthier and spend more years in education, but I can tell you to get as much sleep as you can and interact socially with others.
He stressed that scientists and researchers still have to continue to study the amyloid protein and its impact on Alzheimer’s patients in general.
Paulson said he was not surprised that the drug, Adohelm, which was approved last year, failed to achieve the desired results even in the patients on which it was tried, adding that from now on, other drugs currently being developed by pharmaceutical companies that target the amyloid protein must be examined well first before being released. Any other approvals for new drugs. He added, “We believe that more attention should be paid to other factors and proteins that affect the various types of dementia, which vary between environmental factors, immune factors and other classes of molecules inside the body, such as the “tau molecule”, which is one of the other main proteins that affect the brain. Alzheimer’s patients”.
Paulson believes that developing drugs that target amyloid proteins as a way to treat Alzheimer’s is like trying to install a saddle on a horse’s back following it is already out of the barn, given that Alzheimer’s disease goes through many stages before deposits begin to form on brain cells. It is therefore important from Paulson’s viewpoint to use the tools of modern science to try to study cases of patients who are still in the early stages of memory loss, because this may be more important for attempts to discover drugs to treat Alzheimer’s.
Paulson concluded, “The story of the Adhelem drug underscores the importance of continuing the search for
New treatments for Alzheimer’s disease and dementias associated with this disease.
What happens when you put hot food straight into the fridge?
Warning.. What is the danger of calcium propionate in patty?
Beware.. an overdose of this vitamin threatens your health
What happens to a woman’s body if she stops having sex for a long time?
Boiled or filtered water, which is better?
